Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy: PISCIS Cohort (Spain)

Objective:We analyze the factors related to progression to AIDS or death in HIV-infected patients from the Proyecto para la Informatización del Seguimiento Clínico epidemiológico de los pacientes con Infección por VIH/SIDA (PISCIS) Cohort and we assess the optimal time to initiate highly active antiretroviral therapy (HAART) taking lead time into account. Methods:We selected naive patients who were AIDS-free and initiated HAART after January 1998. Statistical analyses were performed using Cox proportional hazards models. Lead time was defined as the time it took the deferred group with an early disease stage to reach the later stage. The analysis accounting for lead time was performed using multiple imputation methods based on estimates from the pre-HAART period as described elsewhere. Results:Multivariate analysis on 2035 patients (median follow-up = 34.3 months) showed significantly higher hazard ratios (HRs) for a CD4 count <200 cells/μL (HR = 3.79, 95% confidence interval [CI]: 2.18 to 6.57), HIV-1 RNA level >100,000 copies/mL (HR = 1.84, 95% CI: 1.26 to 2.69), and hepatitis C virus (HCV) coinfection (HR = 2.40, 95% CI: 1.65 to 3.49), whereas a lower risk was found for those who started HAART between January 2001 and June 2004 (HR = 0.55, 95% CI: 0.30 to 0.90). When lead time and unseen events were included, we found a higher risk of progression to AIDS among patients who deferred treatment when the CD4 count reached <200 cells/μL (HR = 2.97, 95% CI: 1.91 to 4.63) and 200 to 350 cells/μL (HR = 1.85, 95% CI: 1.03 to 3.33) compared with those who started treatment with CD4 counts from 200 to 350 cells/μL and >350 cells/μL, respectively. Conclusions:Advanced HIV disease, HCV coinfection, and early HAART period were determinants of AIDS progression or death. Lead-time analysis in asymptomatic HIV-infected patients suggests that the best time to start HAART is before the CD4 count falls to lower than 350 cells/μL.

[1]  B. Yip,et al.  Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States. , 2002, AIDS.

[2]  R. Weber,et al.  Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l , 2002, AIDS.

[3]  T. Heeren,et al.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  R. Hogg,et al.  CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/μL , 2006, HIV medicine.

[5]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[6]  J. Robins,et al.  Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. , 2003, American journal of epidemiology.

[7]  J. Margolick,et al.  Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. , 2002, American journal of epidemiology.

[8]  A. Mocroft,et al.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.

[9]  J. Bartlett.  When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4 lymphocyte counts <350 cells/µL , 2004 .

[10]  S. Buskin,et al.  When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[12]  Julio S. G. Montaner,et al.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.

[13]  Timothy R Sterling,et al.  Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. , 2003, The Journal of infectious diseases.

[14]  Roger Detels,et al.  When to initiate highly active antiretroviral therapy: a cohort approach. , 2003, American journal of epidemiology.

[15]  Jonathan AC Sterne,et al.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.

[16]  A. d’Arminio Monforte,et al.  Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. , 2002, Archives of internal medicine.

[17]  M. Battegay,et al.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.

[18]  A Muñoz,et al.  Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. , 2001, American journal of epidemiology.

[19]  A. Phillips,et al.  Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era , 2003, AIDS.

[20]  D. Vlahov,et al.  The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy , 2004, AIDS.

[21]  D. Podzamczer,et al.  [Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]. , 2005, Medicina clinica.

[22]  Richard D Moore,et al.  HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy , 2001, AIDS.

[23]  Gitte Pedersen,et al.  Survival of Persons with and without HIV Infection in Denmark, 19952005 , 2007, Annals of Internal Medicine.

[24]  E. Nicastri,et al.  Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy , 2005, AIDS.

[25]  Jonathan A C Sterne,et al.  HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis , 2006, The Lancet.

[26]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[27]  Maria Deloria-Knoll,et al.  Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata , 2003, Annals of Internal Medicine.

[28]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[29]  Gemma Navarro,et al.  Características clinicoepidemiológicas y tendencias en el tratamiento antirretroviral de una cohorte de pacientes con infección por el virus de la inmunodeficiencia humana. Cohorte PISCIS , 2005 .

[30]  J. Margolick,et al.  Virologic and immunologic values allowing safe deferral of antiretroviral therapy , 2002, AIDS.

[31]  S. Cole,et al.  Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies , 2004, Statistics in medicine.

[32]  J. González,et al.  Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004) , 2004 .

[33]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[34]  A. Moorman,et al.  Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  Hélène Jacqmin-Gadda,et al.  Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001. , 2003, Journal of acquired immune deficiency syndromes.

[36]  E. Daar,et al.  Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. , 2005, The Journal of infectious diseases.

[37]  J. del Romero,et al.  Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting dug users from 1986 to 2001 , 2004, Journal of Epidemiology and Community Health.

[38]  J. González-lahoz,et al.  Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. , 2001, AIDS research and human retroviruses.